Veracyte (VCYT) Cash from Investing Activities (2012 - 2026)
Veracyte's (VCYT) quarterly Cash from Investing Activities came in at -$128.0 million in Q1 2026, down 146.94% year-on-year from $272.6 million in Q1 2025, and down 2256.56% quarter-over-quarter from -$5.4 million in Q4 2025.
Veracyte (VCYT) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Veracyte has disclosed Cash from Investing Activities across 15 years of filings, most recently posting -$128.0 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$128.0 million, down 146.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.4 million (up 23.09% YoY), and the FY2025 annual result was -$9.2 million, up 83.64% from the prior year.
- Cash from Investing Activities came in at -$128.0 million for Q1 2026 at Veracyte, down from -$5.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $48.3 million in Q3 2025 to a low of -$128.0 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$2.8 million (2024), against an average of -$12.2 million.
- Across the five-year window, Cash from Investing Activities slumped 6965.97% in 2022 and surged 2252.68% in 2025, its largest moves.
- Veracyte's Cash from Investing Activities stood at -$26.4 million in 2022, then jumped by 90.55% to -$2.5 million in 2023, then sank by 2068.24% to -$54.1 million in 2024, then surged by 89.97% to -$5.4 million in 2025, then plunged by 2256.56% to -$128.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$128.0 million (Q1 2026), -$5.4 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,010.71 Bn | 30,010.25 Bn | 1.11 Bn | 95.00 Mn |
| 2 | Thermo Fisher Scientific | 179.46 Bn | 176.21 Bn | 7.74 Bn | -8.96 Bn |
| 3 | Danaher | 130.33 Bn | 124.64 Bn | 3.59 Bn | -249.00 Mn |
| 4 | Idexx Laboratories | 44.44 Bn | 44.24 Bn | 722.74 Mn | -33.54 Mn |
| 5 | Agilent Technologies | 37.27 Bn | 35.46 Bn | 990.00 Mn | -77.00 Mn |
| 6 | Iqvia Holdings | 30.70 Bn | 28.73 Bn | 1.36 Bn | -196.00 Mn |
| 7 | Natera | 30.59 Bn | 29.49 Bn | 696.04 Mn | -32.14 Mn |
| 8 | Illumina | 24.86 Bn | 23.71 Bn | 721.00 Mn | -366.00 Mn |
| 9 | Mettler Toledo International | 23.06 Bn | 23.00 Bn | 555.82 Mn | -31.35 Mn |
| 10 | Veracyte | 3.84 Bn | 3.58 Bn | 101.16 Mn | -127.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.96 Mn |
| Mar 31, 2026 | -127.96 Mn |
| Dec 31, 2025 | -5.43 Mn |
| Dec 31, 2025 | -5.43 Mn |
| Sep 30, 2025 | 48.26 Mn |
| Sep 30, 2025 | 48.26 Mn |
| Jun 30, 2025 | -224,000.00 |
| Jun 30, 2025 | -224,000.00 |
| Mar 31, 2025 | -51.82 Mn |
| Mar 31, 2025 | -51.82 Mn |
| Dec 31, 2024 | -54.14 Mn |
| Dec 31, 2024 | -54.14 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | -2.77 Mn |
| Jun 30, 2024 | -2.77 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | -2.50 Mn |
| Dec 31, 2023 | -2.50 Mn |